DE69910362D1 - Anwendung der mesenchymalen stammzellen als immunsuppressiva - Google Patents

Anwendung der mesenchymalen stammzellen als immunsuppressiva

Info

Publication number
DE69910362D1
DE69910362D1 DE69910362T DE69910362T DE69910362D1 DE 69910362 D1 DE69910362 D1 DE 69910362D1 DE 69910362 T DE69910362 T DE 69910362T DE 69910362 T DE69910362 T DE 69910362T DE 69910362 D1 DE69910362 D1 DE 69910362D1
Authority
DE
Germany
Prior art keywords
stem cells
mesenchymal stem
application
immune suppressive
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69910362T
Other languages
English (en)
Other versions
DE69910362T2 (de
Inventor
D Mosca
R Mcintosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osiris Therapeutics Inc
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Application granted granted Critical
Publication of DE69910362D1 publication Critical patent/DE69910362D1/de
Publication of DE69910362T2 publication Critical patent/DE69910362T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/46482—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69910362T 1998-04-03 1999-03-12 Anwendung der mesenchymalen stammzellen als immunsuppressiva Expired - Lifetime DE69910362T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8067898P 1998-04-03 1998-04-03
US80678P 1998-04-03
PCT/US1999/005350 WO1999051275A2 (en) 1998-04-03 1999-03-12 Mesenchymal stem cells as immunosuppressants

Publications (2)

Publication Number Publication Date
DE69910362D1 true DE69910362D1 (de) 2003-09-18
DE69910362T2 DE69910362T2 (de) 2004-06-24

Family

ID=22158925

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69910362T Expired - Lifetime DE69910362T2 (de) 1998-04-03 1999-03-12 Anwendung der mesenchymalen stammzellen als immunsuppressiva

Country Status (11)

Country Link
US (1) US6797269B2 (de)
EP (1) EP1066060B1 (de)
JP (1) JP2002510655A (de)
AT (1) ATE246938T1 (de)
AU (1) AU2999199A (de)
CA (1) CA2326838C (de)
DE (1) DE69910362T2 (de)
DK (1) DK1066060T3 (de)
ES (1) ES2205792T3 (de)
PT (1) PT1066060E (de)
WO (1) WO1999051275A2 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046366A1 (en) * 1998-03-13 1999-09-16 Osiris Therapeutics, Inc. Uses for humane non-autologous mesenchymal stem cells
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CN1318086C (zh) * 2000-07-03 2007-05-30 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4分子用于制备治疗风湿性疾病的药物组合物中的用途
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
JP4294316B2 (ja) 2000-12-06 2009-07-08 ハリリ，ロバート，ジェイ． 胎盤幹細胞の回収方法
ES2629155T3 (es) 2001-02-14 2017-08-07 Anthrogenesis Corporation Matrices de tejido que comprenden células madre placentarias, y métodos para su preparación
EP2336300B1 (de) * 2001-02-14 2015-07-08 Anthrogenesis Corporation Post-partum Säugetier-Plazenta, deren Verwendung und daraus gewonnene Stammzellen
EP2298863B1 (de) * 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymale Stammzellen und deren Verwendungen
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
ES2657382T5 (es) * 2004-03-22 2021-07-12 Mesoblast Int Sarl Células madre mesenquimales y usos de las mismas
AU2012205269B2 (en) * 2004-03-22 2015-08-27 Mesoblast International Sarl Mesenchymal stem cells and uses therefor
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
CA2512667A1 (en) * 2005-01-07 2006-07-07 Takahiro Ochiya Human hepatocyte-like cells and uses thereof
EP2340847A3 (de) * 2005-09-23 2016-11-09 Cellerix, S.A. Zellpopulationen mit immunoregulierenden Aktivität, Verfahren zur Isolierung und Verwendung
MX343814B (es) 2005-10-13 2016-11-24 Anthrogenesis Corp Inmunomodulación usando celulas madre de la placenta.
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
JP2009521930A (ja) 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞及び第２供給源由来幹細胞の共存培養
NZ569562A (en) 2005-12-29 2012-04-27 Anthrogenesis Corp Placental stem cell populations, CD200
ES2415855T3 (es) 2006-01-13 2013-07-29 Osiris Therapeutics, Inc. Células troncales mesenquimatosas que expresan el receptor de TNF
AU2007208368B2 (en) 2006-01-23 2013-05-23 Abt Holding Company MAPC therapeutics without adjunctive immunosuppressive treatment
LT2772535T (lt) 2006-05-31 2022-08-25 Children's Medical Center Corporation Abc5 atžvilgiu teigiamos mezenchiminės kamieninės ląstelės kaip imunomoduliatoriai
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
WO2008054825A2 (en) 2006-11-03 2008-05-08 Aastrom Biosciences, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
NZ612888A (en) 2007-02-12 2015-02-27 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
EP2155860B1 (de) 2007-05-03 2014-08-27 The Brigham and Women's Hospital, Inc. Multipotente stammzellen und ihre verwendung
DE102007028687A1 (de) * 2007-06-21 2008-12-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Therapeutische Zusammensetzung zur Behandlung einer Autoimmunerkrankung, umfassend eine autologe Antigenzusammensetzung, sowie Verfahren und Vorrichtungen zur autologen Antikörper- und Antigenproduktion
EP2185689A2 (de) 2007-08-09 2010-05-19 Genzyme Corporation Verfahren zur behandlung von autoimmunerkrankungen mit mesenchymalen stammzellen
KR20210022148A (ko) 2007-09-28 2021-03-02 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
ES2595103T3 (es) * 2007-10-17 2016-12-27 Txcell Células Tr1, células madre mesenquimales y usos de estas
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
US20110044958A1 (en) * 2008-03-14 2011-02-24 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for the prevention and repair of inflammatory states
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
EP2279246A4 (de) * 2008-05-02 2012-03-28 Massachusetts Inst Technology Verfahren und zusammensetzungen zur modulation immunologischer toleranz
KR20230031991A (ko) 2008-08-20 2023-03-07 셀룰래리티 인코포레이티드 단리된 태반 세포를 사용한 뇌졸중 치료
PE20110400A1 (es) 2008-08-20 2011-06-22 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas
CN102176919A (zh) 2008-08-22 2011-09-07 人类起源公司 用胎盘细胞群治疗骨缺损的方法和组合物
EP2367932B1 (de) 2008-11-19 2019-06-12 Celularity, Inc. Aus fruchtwasser stammende adhärente zellen
WO2010068707A2 (en) * 2008-12-09 2010-06-17 University Of Southern California Stem cell modified animal model for aging-related degenerations, stem cell based methods and compositions for extending lifespan and treating sle-like autoimmune diseases
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
BR112012001329B1 (pt) * 2009-07-21 2021-04-13 Abt Holding Company Uso de células progenitoras adultas multipotentes (mapcs), e, métodos para obter células progenitoras adultas multipotentes (mapcs) com uma potência desejada e para aumentar a potência de células progenitoras adultas multipotentes (mapcs)
ES2784183T3 (es) * 2009-12-08 2020-09-22 Univ Illinois Procedimientos de uso y aparato para modulación inmunitaria de células madre
DK3284818T3 (da) 2010-01-26 2022-06-20 Celularity Inc Behandling af knoglerelateret kræft ved hjælp af placenta stamceller
US9254302B2 (en) 2010-04-07 2016-02-09 Anthrogenesis Corporation Angiogenesis using placental stem cells
JP2013523823A (ja) 2010-04-08 2013-06-17 アントフロゲネシス コーポレーション 胎盤幹細胞を用いるサルコイドーシスの治療
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
KR20220053695A (ko) 2010-07-13 2022-04-29 셀룰래리티 인코포레이티드 천연 킬러 세포의 생성 방법
EP2624845A4 (de) 2010-10-08 2015-09-09 Mesoblast Internat S Rl Verbesserte msc-präparate
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
AU2011352036A1 (en) 2010-12-31 2013-07-18 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012166844A2 (en) 2011-06-01 2012-12-06 Anthrogenesis Corporation Treatment of pain using placental stem cells
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
JP2015522026A (ja) 2012-06-27 2015-08-03 オルバン バイオテック エルエルシー 糖尿病を処置するためのｃｔｌａ４融合タンパク質
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
EP3865573A1 (de) 2013-02-19 2021-08-18 Children's Medical Center Corporation Abcb5(+)-stammzellen zur behandlung von augenerkrankungen
SG11201508403XA (en) 2013-04-12 2015-11-27 Saverio Lafrancesca Improving organs for transplantation
WO2014182994A1 (en) 2013-05-10 2014-11-13 Children's Medical Center Corporation Wound healing and tissue engineering
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015023147A1 (ko) * 2013-08-16 2015-02-19 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
PT3091991T (pt) * 2013-12-13 2020-02-04 Swedish Stromabio Ab Composições imunomodulatórias
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
KR20150136389A (ko) * 2014-05-27 2015-12-07 삼성전자주식회사 관절염 예방 또는 치료용 조성물, 키트, 및 이를 이용한 관절염 예방 또는 치료 방법
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
KR20180105705A (ko) 2016-02-04 2018-09-28 롱에버론 엘엘씨 백신 보조제로서의 중간엽 줄기 세포 및 그의 사용 방법
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
EP3464565A4 (de) 2016-05-25 2020-01-01 Terumo BCT, Inc. Zellexpansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (de) 2017-03-31 2020-05-27 Terumo BCT, Inc. Zellexpansion
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖
CN114480413B (zh) * 2022-01-14 2022-11-04 北京贝来生物科技有限公司 一种活化肿瘤免疫应答的基因修饰干细胞制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5747299A (en) * 1994-06-23 1998-05-05 The Board Of Trustees Of The Leland Stanford Junior University Anergy genes

Also Published As

Publication number Publication date
JP2002510655A (ja) 2002-04-09
WO1999051275A2 (en) 1999-10-14
ES2205792T3 (es) 2004-05-01
DE69910362T2 (de) 2004-06-24
US20020044923A1 (en) 2002-04-18
WO1999051275A3 (en) 1999-12-09
CA2326838C (en) 2008-12-23
AU2999199A (en) 1999-10-25
EP1066060A2 (de) 2001-01-10
ATE246938T1 (de) 2003-08-15
PT1066060E (pt) 2003-12-31
EP1066060B1 (de) 2003-08-13
CA2326838A1 (en) 1999-10-14
US6797269B2 (en) 2004-09-28
DK1066060T3 (da) 2003-11-24

Similar Documents

Publication Publication Date Title
DE69910362D1 (de) Anwendung der mesenchymalen stammzellen als immunsuppressiva
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
NO331101B1 (no) In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet.
ES2539411T3 (es) PD-1, receptor para la B7-4 y su utilización
DE69736669D1 (de) Zelladhäsionsinhibitoren
PT975359E (pt) Potencializacao da resposta imunitaria atraves de distribuicao de compostos que se ligam a uma dipeptidase citoplasmatica
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
ATE386930T1 (de) Mischverfahren
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
IL179441A (en) Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme
DE69534595D1 (de) Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
ATE331791T1 (de) Phosphodiesterase 10
NZ330475A (en) Antibodies, and use thereof in measuring lipid peroxidation in biological samples and method for inducing inflammation
EA200702092A1 (ru) Липосомная композиция для индукции иммунитета
DE122007000025I1 (de) Für menschliches Papillomavirus stamm 18 kodierende DNS
DK1007666T3 (da) Neurturinreceptor
DK0914605T3 (da) Molekylemodel for VLA-4-inhibitorer
EP1572133A4 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
TR200400941T4 (tr) Lipid kinazların modülatörlerinin taranması için yöntemler ve bileşimler
WO1999024835A3 (en) An immunoassay for procollagen-iii-c-terminal propeptide
SE9603344D0 (sv) Method and apparatus for detecting substances
AU9437598A (en) Method and kit for identifying interactions between proteins or peptides
ATE132896T1 (de) Methoden zur verwendung von an humanen klasse-ii- histokompatibilitätsantigenen mangelnden zellinien
ATE307201T1 (de) Srcr domäne-enthaltendes protein
BR9105983A (pt) Anticorpos monoclonais que diferenciam entre proteinas de sequencias nativa e modificada

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. VOLKER VOSSIUS, CORINNA VOSSIUS, TILMAN VOSSIU